| CGRPs | Calcitonin Gene-Related Products |
|---|---|
| CPSC | congenital paucity of secondary synaptic clefts [syndrome]; Consumer Products Safety Commission |
| ERPC | evacuation of retained products of conception |
| FbDP | fibrin degradation products |
| FgDP | fibrinogen degradation products |
| waste products | Debris resulting from a process that is of no further use to the system producing it. The concept includes materials discharged from or stored in a system in inert form as a by-product of vital activities. (12 Dec 1998) |
|---|---|
| conventional forest products | Any commercial roundwood product (boards, dimension lumber, pulp and paper products) except fuelwood. (05 Dec 1998) |
| poultry products | Food products manufactured from poultry. (12 Dec 1998) |
| household products | Substances or materials used in the course of housekeeping or personal routine. (12 Dec 1998) |
| specialty chemicals and products | Chemicals and chemical products used in a research, industrial, or household setting. Included here are the specific drug preparations, as well as the substances involved in the manufacture and stabilization of pharmaceutical preparations and agricultural agents. (12 Dec 1998) |
| natural products | Naturally occurring compounds that are end products of secondary metabolism; often, they are unique compounds for particular organisms or classes of organisms. (05 Mar 2000) |
| dairy products | Raw and processed or manufactured milk and milk-derived products. These are usually from cows (bovine) but are also from goats, sheep, reindeer, and water buffalo. (12 Dec 1998) |
| orphan products | Drugs, biologicals, and medical devices (including diagnostic in vitro tests) that may be useful in common or rare diseases but which are not considered commercially viable. Synonym: orphan drugs. (05 Mar 2000) |
| fibrin degradation products | <haematology, investigation> A test that measures fibrin degradation products which result from the dissolution of a blood clot. Normal value is less than 10 mcg/ml (micrograms per millilitre). They may be increased in conditions such as burns, placental abruption, heart disease, DIC, after massive blood transfusion, hypoxia, intrauterine foetal death, portacaval shunt, leukaemia, transfusion reaction, transplant rejection, sepsis, renal failure and preeclampsia. Acronym: FDP (23 Sep 2002) |
| fibrin fibrinogen degradation products | <chemical> Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. Fdp and their complexes profoundly impair the haemostatic process and are a major cause of haemorrhage in intravascular coagulation and fibrinolysis. Pharmacological action: antithrombins. (12 Dec 1998) |
| fish products | Food products manufactured from fish (e.g., fish flour, fish meal). (12 Dec 1998) |
| academic medical centres | Medical complexes consisting of medical school, hospitals, clinics, libraries, administrative facilities, etc. (12 Dec 1998) |
| advance medical directives | Advance directives preserve the person's right to accept or reject a course of medical treatment even after that person becomes mentally or physically incapacitated to the point of being unable to communicate those wishes. There ared two basic types of advance directives: (1) a living will, in which the person outlines specific treatment guidelines that are to be followed by health care providers; (2) a health care proxy (also called a power of attorney for healthcare decision making) in which the person designates a trusted individual to make medical decisions in the event that he or she becomes too incapacitated to make such decisions. Advance directive requirements vary greatly from one jurisdiction to another and should therefore be drawn up in consultation with an attorney who is familiar with the laws of the particular jurisdiction. (This entry is based upon material from the National MS Society). (12 Mar 2000) |
| american medical association | Professional society representing the field of medicine. (12 Dec 1998) |
| genetics, medical | A field of human genetics which entails the reliable prediction of certain human disorders as a function of the lineage and/or genetic makeup of any two parents or potential parents. (12 Dec 1998) |
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|
Á¦Ç°¸í |
ÆÇ¸Å»ç |
º¸ÇèÄÚµå | ¼ººÐ/ÇÔ·® | ±¸ºÐ/º¸Çè±Þ¿© |
|---|